-
Mashup Score: 18What is the rationale for monitoring secondary malignancies after BCMA and CD19 CAR T cell therapy - 2 day(s) ago
The Lymphoma Hub and Multiple Myeloma Hub were pleased to speak to Anna Sureda, Catalan Institute of Oncology, Barcelona, ES. We asked, What is the rationale…
Source: www.youtube.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 14Lisocabtagene maraleucel as a second-line treatment for R/R LBCL: PROs from the PILOT study - 4 day(s) ago
Here, we summarize a health-related quality of life and patient-reported outcomes analysis from the phase II PILOT trial, published by Gordon et al. in Haematologica.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Correlation between MRD at the end of induction and EFS in pediatric T-cell lymphoblastic lymphoma - 9 day(s) ago
Here, we summarize a subgroup analysis of the Children’s Oncology Group AALL1231 trial investigating the correlation between MRD at the end of induction and event-free survival in pediatric patients with T-cell lymphoblastic lymphoma published by Hayashi et al.1 in Blood.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 10Waldenström’s macroglobulinemia | Lymphoma Hub - 10 day(s) ago
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6STARGLO trial of glofitamab: primary endpoint met in R/R DLBCL - 12 day(s) ago
Results obtained from the phase III STARGLO trial showed that glofitamab met its primary endpoint of overall response in patients with R/R DLBCL who received at least one prior line of therapy.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6
During the 6th European CAR T-Cell Meeting, the Lymphoma Hub was pleased to speak to the president of EBMT, Anna Sureda, Catalan Institute of Oncology, Barcelona, ES.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 13Venetoclax monotherapy for patients with R/R CLL: Results from the phase III VENICE-1 trial - 18 day(s) ago
Here we summarize the results from the VENICE-1 trial evaluating venetoclax monotherapy in patients with R/R CLL, published by Kater et al.1 in Lancet Oncology.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2SYMPATICO: Is ibrutinib combined with venetoclax safe and effective in patients with R/R MCL? - 22 day(s) ago
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Michael Wang, MD Anderson Cancer Center, Houston, US. We asked, Is ibrutinib combined with venetoclax safe and effective in patients with R/R MCL?
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8Polatuzumab vedotin in combination with venetoclax and rituximab for patients with R/R DLBCL - 25 day(s) ago
Here, we summarize results from a phase Ib/II trial assessing the safety and efficacy of polatuzumab vedotin in combination with rituximab and lenalidomide in patients with R/R DLBCL.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 13GLOW trial: A 4-year update on fixed-duration ibrutinib + venetoclax in previously untreated CLL - 1 month(s) ago
Here, we summarize the 4-year follow-up data from the phase III GLOW trial investigating fixed duration ibrutinib + venetoclax vs chlorambucil + obinutuzumab in previously untreated chronic lymphocytic leukemia published by Niemann, et al.1 in The Lancet Oncology.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
🎥 The @lymphomahub and @MM_Hub were pleased to speak to @AnnaSureda5. We asked, What is the rationale for monitoring secondary malignancies after BCMA and CD19 CAR T-cell therapy? Watch here: https://t.co/P150oJr7Iy #mmsm #myeloma #lymphoma #lymsm https://t.co/LpPPLqkedu